The team at Divine Skin has been working to maintain strong growth and exceed expectations across its diverse consumer goods business and accelerate development through its strong biotechnology program. Some highlights for the year include:

 

RECORD 2010 REVENUE.  Divine Skin started the year by announcing record sales for 2010 ($5.4 million), up $1.9 million or 55 percent over 2009.

 

RECORD 2011 QUARTERS.  We postedrecord sales again in Q1 ($2.2 million) and Q2 ($2.3 million) of this year, and the first nine-month period ($6.6 million) was up 74 percent, reaping the benefits of production investments and explosive demand.

 

SALONS.  In May, DS Laboratories announced new agreements with four distributors that supply 27,000 salons and professionals in the Northwest, Southwest, Southeast, and Midwest.

 

NEIMAN MARCUS.  Prestigious fashion retailer Neiman Marcus picked up our super-premium Sigma Skin line for hair and skin.

 

AUDITORS.  Top-30 auditing firm Cherry, Bekaert & Holland LLP began advising us, bringing valuable experience with publicly traded manufacturers and lending credibility to financial statements.

 

BRAZIL.  A new Brazilian distributor conducted the successful trials and earned the required certificates needed to import into that burgeoning market of 201 million eager consumers.

 

ORAL ANALGESIC.  We announced our foray into pharmaceuticals with an oral analgesic to compete with Tylenol, Advil, and aspirin. Like our other products, it targets the market that appreciates more advanced biotechnology.

 

NUTRAORIGIN.  Expanding into nutritional supplements, Divine Skin acquired rights to NutraOrigin, with 63 formulas that can be incorporated easily into any health regimen.

 

NANOXIDIL.  The company introduced a new compound, Nanoxidil, engineered to surpass minoxidil for efficacy and tolerability. It debuted in new Spectral.DNC-N.

 

ASTRESSIN-B.  DS Labs became the first biotech brand to commercialize a product based on astressin-B, a peptide (protein fragment) newly discovered to regrow hair on bald mice. It debuted in new Spectral.F7.

 

CAPITALIZATION.  Divine Skin secured new capital through Littlebanc Advisors to be used to build our mounting inventory and service our expanding distribution.

 

API SOLUTION 9.  Research rolled out API Solution 9, a customizable topical kit to be sold by physicians designed for even the most challenging hair loss problems. It delivers unprecedented materials with extensive clinical trials, and it has no competitor.

 

WHOLE FOODS.  NutraOrigin tested successfully in Whole Foods, a chain of 297 retail stores in the United States, plus seven in Canada and six in the United Kingdom.

 

ZACKS INVESTMENT RESEARCH.  Zacks gave Divine Skin an “outperform” rating and a six-month target price of $0.65 per share.

 

Divine Skin announces that its plans for expansion in 2012 are even more aggressive, and that they will further diversify its core business.

 

About Divine Skin

 

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.

DS Laboratories, its flagship brand, offers high-performance topical solutions with broad spectrum of activity across a range of personal care applications. Bioavailability is enhanced through encapsulation.

 

 

Investor relations contact:

 

Abner Silva

Investor Relations

Divine Skin Inc.

1.407.342.4112

investors@divineskin.com